Long-term treatment with a new non-ergot long-acting dopamine agonist, CV 205-502, in women with hyperprolactinaemia.
Twenty-four hyperprolactinaemic women were treated for 6 months with the new, non-ergot, long-acting dopamine agonist, CV 205-502. The treatment resulted in normalization of PRL secretion in 17 of the 24 women at once-daily doses of 0.05 to 0.15 mg of the drug. Sixteen of these women as well as 4 of those who remained hyperprolactinaemic had regular menstrual bleeding. Five of the patients had previously discontinued bromocriptine therapy because of adverse effects but had no problems tolerating CV 205-502. Of three bromocriptine-resistant women, two responded partially while one also remained unresponsive to CV 205-502 treatment. Mild to moderate galactorrhoea was recorded at baseline in 19 of the 24 women. After 6 months' treatment mild galactorrhoea was still present in six patients, four of whom had attained normal PRL levels. Side-effects were mild and transient. CV 205-502 seems to be a valuable compound in the management of patients with hyperprolactinaemia.
Rasmussen
C
C
Department of Obstetrics and Gynaecology, Uppsala University, Sweden.
Bergh
T
T
Wide
L
L
Brownell
J
J
D000328:Adult; D000634:Aminoquinolines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015259:Dopamine Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005687:Galactorrhea / Q000188:drug therapy; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy*; D008875:Middle Aged; D013997:Time Factors
D000634:Aminoquinolines; D015259:Dopamine Agents; C046650:quinagolide